# Beijing Datsing Bio-tech Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/beijing-datsing-bio-tech-co

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.datsing.com
- Total disclosed funding: $11M
- Latest round: Series A (Aug 22, 2014)
- Investors on record: 3

## About

Based in Beijing, China and founded in 2001, Beijing Datsing Bio-tech Co., Ltd. is a biotechnology that focuses on the research and development of regenerative medicine materials. In May 2026, Nanjing Pharmaceutical Co., Ltd., through a soon-to-be-established fund managed by Nanjing New Industry Investment, agreed to acquire a 50.98 % majority stake in Beijing Kejian Technology Co., Ltd. for approximately CNY 407.82 million.

The company's main products include clear biopaper, No. 1 dental implants and tooth desensitizer Aominqing, etc. Aominqing has the functions of relieving and reducing gum bleeding, inhibiting and reducing dental plaque. The company's products are used in minimally invasive surgery, oral medicine, and regenerative medicine.

The company generates revenue from the sales of biomedical material, stem cell solutions and regenerative medicine.

## Funding rounds

- Series A, Aug 22, 2014, $11M — NLVC, Hidea Investment
- Angel, May 23, 2013 — Tsinghua Innovation Ventures

## Investors

- Tsinghua Innovation Ventures (https://capitalatlas.ai/funds/tsinghua-innovation-ventures) — Angel
- NLVC (https://capitalatlas.ai/funds/nlvc) — Series A
- Hidea Investment (https://capitalatlas.ai/funds/hidea-investment) — Series A